Gilead-linked filings: ARTISTRY-1, KeY Treat post results; iMMagine-4 registers at Kite

Three Gilead-affiliated studies updated their registry records this week, spanning HIV, hepatitis C and multiple myeloma.

• "ARTISTRY-1" (NCT05502341), Gilead's phase 2/3 trial testing bictegravir/lenacapavir switch regimens against stable baseline therapy in virologically suppressed people with HIV-1, posted results. The trial enrolled 689 participants¹ and results were first posted on 2026-10-21¹, with primary completion listed as actual on 2025-09-29.
• The "Kentucky Viral Hepatitis Treatment (KeY Treat) Study" (NCT03949764), a completed phase 4 trial led by Jennifer Havens with Gilead Sciences among its collaborators alongside NIDA, NCI, the University of Kentucky, Icahn School of Medicine at Mount Sinai and the University of Bristol², also posted results. The study tested sofosbuvir/velpatasvir, a 12-week, once per day, pan-genotypic DAA, made possible by a significant drug donation from Gilead Sciences², in Perry County, Kentucky, enrolling 380 participants (actual)², with results first posted on 2026-10-20.
• "iMMagine-4" (NCT07887672), a new phase 3 trial sponsored by Kite, A Gilead Company, registered this week. The study will compare anitocabtagene autoleucel versus quadruplet-based standard of care therapy in participants with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant³, with an estimated enrollment of 600 participants³ and status listed as not yet recruiting.